Impact of intestinal microbiota and its metabolites on SARS-CoV-2 infection

• Grant number: 20/04583-4
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2020
• End date: March 31, 2022
• Field of knowledge: Biological Sciences - Immunology - Cellular Immunology
• Principal Investigator: Marco Aurélio Ramirez Vinolo
• Grantee: Marco Aurélio Ramirez Vinolo
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• City of the host institution: Campinas
• Associated researchers: Ana Paula Duarte de Souza ; William Marciel de Souza
• Associated research grant: 18/15313-8 - Investigation of the molecular mechanisms involved in the interaction between microbiota-derived metabolites and host cells during inflammation, AP.JP2

Abstract

The Covid-19 pandemic has impacted public health dramatically in several countries. In this context, understanding the factors related to the serious forms of Covid-19 is essential for prevention and, possibly, treatment of patients. Recent studies show that the intestinal microbiota and its products play a fundamental role in respiratory infections by other viruses including respiratory syncytial virus and Influenza virus. However, it is not known whether there is a relationship between changes in the microbiota and infection by COVID-19. In this project, we will use experimental approaches already used by the group to understand the relationship between intestinal microbiota/its products and respiratory viral infection by SARS-CoV. Briefly, we will use experimental models in which we change the intestinal microbiota and its metabolite production through the use of antibiotics, supplementation with microbiota's metabolites or diets that alter the endogenous production of these products, and we will analyze your response to SARS-CoV infection. Mice kept under different experimental conditions (diets, oral supplementation with metabolites or antibiotics) will be infected with SARS-CoV and analyzed for disease progression (weight variation and clinical signs) and subsequently euthanized for analysis of viral load, inflammatory mediators, and histological changes in the lung. In addition, we will analyze the amount of virus present in feces and the intestinal production of short-chain fatty acids and the composition of the intestinal microbiota. The data obtained will be complemented by analyzes performed with human cell lines and samples from infected patients. (AU)

Scientific publications

(6)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

RODRIGUES, PATRICIA BRITO; DOS SANTOS PEREIRA GOMES, ARILSON BERNARDO; GENARO, LIVIA MOREIRA; PASCOAL, LIVIA BITENCOURT; DUARTE DE SOUZA, ANA PAULA; LEAL, RAQUEL FRANCO; RAMIREZ VINOLO, MARCO AURELIO; GUEST, PC. Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known?. IDENTIFCATION OF BIOMARKERS, NEW TREATMENTS, AND VACCINES FOR COVID-19, v. 1327, p. 14-pg., 2021-01-01. (20/02312-3, 20/04583-4, 19/14342-7)

SACCON, TATIANA DANDOLINI; MOUSOVICH-NETO, FELIPPE; LUDWIG, RAISSA GUIMARAES; CARREGARI, VICTOR CORASOLLA; DOS ANJOS SOUZA, ANA BEATRIZ; DOS PASSOS, AMANDA STEPHANE CRUZ; MARTINI, MATHEUS CAVALHEIRO; BARBOSA, PRISCILLA PASCHOAL; DE SOUZA, GABRIELA FABIANO; MURARO, STEFANIE PRIMON; et al. SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner. NATURE COMMUNICATIONS, v. 13, n. 1, p. 15-pg., 2022-09-29. (20/08716-9, 20/04558-0, 19/05155-9, 21/10373-5, 13/07607-8, 20/04919-2, 20/04746-0, 17/01184-9, 17/23920-9, 16/24163-4, 16/00194-8, 18/21635-8, 19/00098-7, 20/05040-4, 17/08264-8, 20/04579-7, 19/26119-0, 19/04726-2, 20/04583-4, 20/15959-5)

BRUNETTI, NATALIA S.; DAVANZO, GUSTAVO G.; DE MORAES, DIOGO; FERRARI, ALLAN J. R.; SOUZA, GABRIELA F.; MURARO, STEFANIE PRIMON; KNITTEL, THIAGO L.; BOLDRINI, VINICIUS O.; MONTEIRO, LAUAR B.; VIRGILIO-DA-SILVA, JOO VICTOR; et al. SARS-CoV-2 uses CD4 to infect T helper lymphocytes. eLIFE, v. 12, p. 26-pg., 2023-07-31. (20/04558-0, 15/15626-8, 19/06459-1, 19/04726-2, 19/16116-4, 19/05155-9, 19/13552-8, 16/18031-8, 19/00098-7, 20/04583-4, 16/00194-8, 21/08354-2, 19/17007-4, 19/22398-2, 17/01184-9, 19/14465-1, 20/04579-7, 13/08293-7, 18/14933-2, 17/23920-9, 19/06372-3, 16/24163-4, 16/23328-0, 20/04919-2, 20/04746-0)

CODO, ANA CAMPOS; DAVANZO, GUSTAVO GASTAO; MONTEIRO, LAUAR DE BRITO; DE SOUZA, GABRIELA FABIANO; MURARO, STEFANIE PRIMON; VIRGILIO-DA-SILVA, JOAO VICTOR; PRODONOFF, JULIANA SILVEIRA; CARREGARI, VICTOR CORASOLLA; OLIVEIRA DE BIAGI JUNIOR, CARLOS ALBERTO; CRUNFLI, FERNANDA; et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 alpha/Glycolysis-Dependent Axis. Cell Metabolism, v. 32, n. 3, p. 15-pg., 2020-09-01. (19/00098-7, 20/04558-0, 20/04522-5, 19/06372-3, 16/18031-8, 15/15626-8, 16/23328-0, 17/01184-9, 20/04919-2, 20/04583-4, 20/04579-7, 18/22505-0, 20/04746-0)

RODRIGUES, PATRICIA BRITO; GOMES, GIOVANNI FREITAS; ANGELIM, MONARA K. S. C.; SOUZA, GABRIELA F.; MURARO, STEFANIE PRIMON; TOLEDO-TEIXEIRA, DANIEL A.; CRUZ RATTIS, BRUNA AMANDA; PASSOS, AMANDA STEPHANE; PRAL, LAIS PASSARIELO; RODOVALHO, VINICIUS DE REZENDE; et al. Impact of Microbiota Depletion by Antibiotics on SARS-CoV-2 Infection of K18-hACE2 Mice. CELLS, v. 11, n. 16, p. 16-pg., 2022-08-01. (20/10282-7, 20/04558-0, 20/05211-3, 19/06372-3, 20/04583-4, 20/04746-0)

PASCOAL, LIVIA BITENCOURT; RODRIGUES, PATRICIA BRITO; GENARO, LIVIA MOREIRA; DOS SANTOS PEREIRA GOMES, ARILSON BERNARDO; TOLEDO-TEIXEIRA, DANIEL AUGUSTO; PARISE, PIERINA LORENCINI; BISPO-DOS-SANTOS, KARINA; SIMEONI, CAMILA LOPES; GUIMARAES, PAULA VERI; BUSCARATTI, LUCAS ILDEFONSO; et al. Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples. GUT MICROBES, v. 13, n. 1, p. 1-9, JAN 1 2021. (20/04558-0, 20/04583-4, 20/02448-2, 20/02312-3, 19/14342-7, 20/04746-0, 17/26908-0, 20/04579-7, 20/04919-2, 19/06372-3, 13/07607-8, 20/02159-0)